Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | SVP, Chief Compliance Officer | February 27, 2017 | March 01, 2017 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | General Counsel | February 21, 2025 | February 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXION PHARMACEUTICALS, INC.
Report date February 27, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 19,284 |
Ending reported balance
After 2017-02-28 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-02-27 · Sale · Disposed 260 · Balance 15,214 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 2 · 2017-02-28 · Sale · Disposed 330 · Balance 14,884 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 3 · 2017-02-28 · Grant · Acquired 4,400 · Balance 19,284 F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $131.25 · Expires 2027-02-28 | Direct | 8,700 |
Reported balance
After 2017-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-02-28 · Grant · Acquired 8,700 · Balance 8,700 F4: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
F4: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.
Kalaris Therapeutics, Inc.
Report date February 21, 2025 · Filed February 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,517 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Sale · Disposed 106 · Balance 6,517 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 15,058 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,058 F3: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 330 | $131.70 | $43,461.00 |
DisclosureSEC source: 0000899866-17-000058 · wf-form4_148841553225370.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,884 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 260 | $131.20 | $34,112.00 |
DisclosureSEC source: 0000899866-17-000058 · wf-form4_148841553225370.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,214 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 9 | $126.95 | $1,142.55 |
DisclosureSEC source: 0000899866-17-000027 · wf-form4_148658996992757.xml · nonDerivative · entry 2 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,474 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,036 | $125.69 | $130,214.84 |
DisclosureSEC source: 0000899866-17-000027 · wf-form4_148658996992757.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,483 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 09, 2016 Filed Sep 9, 2016 18:23 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 367 | $128.32 | $47,093.44 |
DisclosureSEC source: 0000899866-16-000353 · wf-form4_147345980329358.xml · nonDerivative · entry 1 Miller Edward · CIK 0001619252 · SVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,519 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $128.00 - $128.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.